about
Hepatitis C virus proteinsCurrent molecular methods for the detection of hepatitis C virus in high risk group population: A systematic reviewRole of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins.Monoclonal Antibody AP33 Defines a Broadly Neutralizing Epitope on the Hepatitis C Virus E2 Envelope GlycoproteinIdentification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 BindingThe Neutralizing Activity of Anti-Hepatitis C Virus Antibodies Is Modulated by Specific Glycans on the E2 Envelope ProteinStructural elucidation of critical residues involved in binding of human monoclonal antibodies to hepatitis C virus E2 envelope glycoproteinMass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycansHepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis CProtein Kinase A-Dependent Step(s) in Hepatitis C Virus Entry and InfectivityA genome-wide genetic screen for host factors required for hepatitis C virus propagationMutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entryBlocking Hepatitis C Virus Infection with Recombinant Form of Envelope Protein 2 EctodomainAntiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virusRecombinant hepatitis C virus-envelope protein 2 interactions with low-density lipoprotein/CD81 receptors.Natural reservoirs for homologs of hepatitis C virus.Evolutionary interactions between N-linked glycosylation sites in the HIV-1 envelopeElicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal modelsCharacterization of HCV genotype 5a envelope proteins: implications for vaccine development and therapeutic entry target.Inhibition of hepatitis C virus 3a genotype entry through Glanthus Nivalis Agglutinin.Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4Hepatitis C virus e2 protein ectodomain is essential for assembly of infectious virionsLast stop before exit - hepatitis C assembly and release as antiviral drug targets.Griffithsin has antiviral activity against hepatitis C virusStructural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody.Coordinate deletion of N-glycans from the heptad repeats of the fusion F protein of Newcastle disease virus yields a hyperfusogenic virus with increased replication, virulence, and immunogenicitySelection of a hepatitis C virus with altered entry factor requirements reveals a genetic interaction between the E1 glycoprotein and claudinsCharacterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entryHeterogeneity and new epitopes of hepatitis C virus genotype 4.Characterization of hepatitis C virus intra- and intergenotypic chimeras reveals a role of the glycoproteins in virus envelopment.Post-translational modifications of hepatitis C viral proteins and their biological significance.GB Virus C/Hepatitis G Virus Envelope Glycoprotein E2: Computational Molecular Features and Immunoinformatics Study.Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA.Chloroplast-derived vaccines against human diseases: achievements, challenges and scopes.Immunotherapeutic potential of neutralizing antibodies targeting conserved regions of the HCV envelope glycoprotein E2.Hepatitis C virus evasion mechanisms from neutralizing antibodiesThe role of HCV e2 protein glycosylation in functioning of virus envelope proteins in insect and Mammalian cells.Neutralizing monoclonal antibodies against hepatitis C virus E2 protein bind discontinuous epitopes and inhibit infection at a postattachment step.HCV glycoprotein structures: what to expect from the unexpected.Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein.
P2860
Q24563969-E69B2F4C-1732-4396-B171-4F5A35D62F95Q26851978-C0A4A6D9-5669-479E-9234-283C211D9A70Q27469844-AC2D75E1-9ED0-4CE1-9C97-8B427D070E91Q27470798-C7A41E2F-0752-44F0-937B-84122690D433Q27477468-FD1E540D-D964-4BA1-B88D-B8EF34622539Q27481009-99C8E9EF-C094-4435-A1BF-9FF0422D2DA3Q27485636-B27481BB-6E74-4E70-9B64-332DD4D14957Q27485679-4973D625-D3AB-4022-BCBB-7B2CA15B743BQ27486537-6D75AB3D-4582-4579-B030-32677BB002FCQ27486784-C65BAAE4-D4DA-4CA8-84E7-6E0DB7B85C21Q27489773-49AD0237-7321-4282-B2CF-4744A6032B21Q27489898-535BFAAB-CACC-4BFD-A651-9D13185038FAQ27490335-58DC8D69-2695-49F5-9FE3-C9EAECF5E763Q28488338-56BA38E9-6055-4878-AF6B-F6CBE348D964Q30375044-B874F35B-222C-4629-8D0D-1061CAC004DAQ30375258-751C1C76-F25E-4D3E-9685-7D2C1E2268DDQ33269794-7DE5A3EA-3CD1-44F1-A8B9-A4A0CDC24C9BQ33867634-EF02E17D-8187-4BB4-AB96-7491F5A21624Q34864567-A86296F5-0599-44C6-BD1B-1899FE5C6B20Q35053124-3A8809CA-BB5B-4CFC-A917-102FA757D7E6Q35172385-AFA92546-8748-4AA5-B09C-79F403407EA6Q35212817-6AFAE4B8-B82D-4973-B5AD-D17F143E3FB3Q35261158-EF74DD06-79C7-406F-97E2-EF2D021A6362Q35363633-905ADD25-0DA0-433B-B351-7EE9F398C76EQ35450992-7AB6DEF7-D0E5-41BF-97D1-09489EB932CAQ35826122-E97E7290-C984-47EA-8BDB-97D75400ADC0Q36105419-16593FC1-A5F4-4173-8E39-6F3E48E15E66Q36559862-97E2CB63-92FC-47E0-8858-5EF7082A338CQ37228726-ED36E426-3167-400F-9126-1EA2A0916B11Q37336814-9946B08F-6A44-41E6-89F7-1A4FFCC1B7EAQ37408926-5C9B30B2-CD2A-4B49-AEF8-3FEBF375BCE4Q37424363-C82979A0-1C0E-476D-8D1A-39025513D673Q37533386-42F87786-1945-4F92-AF08-72E1F25BCBC3Q37859086-237C0B16-746C-475F-A25F-E232CA60D8D6Q37859393-B61EF939-3A81-4B35-B91E-13A0DD36FC1EQ37967737-BF1A89FF-10BC-469C-A7F6-7B45CF63037AQ38299373-4A4A9123-7AE7-485E-B0E3-EE5FAB3096A9Q38335402-ECF44F9C-FEEF-4618-9282-E098D4BC07B9Q38384140-FB0FF724-3C24-49F0-93B9-D625B693BCF5Q38710443-592C9E9A-807E-4D03-9474-AFFB4347E64A
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Glycosylation of hepatitis C virus envelope proteins.
@ast
Glycosylation of hepatitis C virus envelope proteins.
@en
type
label
Glycosylation of hepatitis C virus envelope proteins.
@ast
Glycosylation of hepatitis C virus envelope proteins.
@en
prefLabel
Glycosylation of hepatitis C virus envelope proteins.
@ast
Glycosylation of hepatitis C virus envelope proteins.
@en
P1433
P1476
Glycosylation of hepatitis C virus envelope proteins.
@en
P304
P356
10.1016/S0300-9084(03)00004-X
P577
2003-03-01T00:00:00Z